Three years of pharmaceutical reform, five major changes, affecting all pharmaceutical companies
Source:赛柏蓝
|
Author:赛柏蓝
|
Published time: 2018-08-20
|
1365 Views
|
Share:
On the occasion of the 3rd anniversary of document No. 44 (2015.08.18), we hereby review the achievements of pharmaceutical reform in the past 3 years from the aspects of innovation, imitation, data verification, flight inspection, international standards and so on. 
New drugs should be "new" No. 44 of the State Council defines new drugs from the current "did not go on sale in the territory of China medicine" changed to "not publicly listed company in China selling drugs", return to the real connotation of "new drug", of course for new drug research and development are also put forward higher requirements, but no. 44 a landmark document encourage pharmaceutical innovation, created a good policy environment for Chinese pharmaceutical innovation, from then on, China pharmaceutical innovation into the fast lane, has made some progress. 1. The number of independent new drug declarations in China has increased significantly
2. The number of biological analogues in research in China has ranked first in the world
